BioSpace News Archive

Unlike the professional skills and experiences you gain through formal training or education, soft skills are those elusive interpersonal skills, personality traits, character attributes, or communication styles that will determine how you interact with your colleagues and the success or failure of the relationships you form in the workplace.

Pharming Group N.V. presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2018.

Initial data from the first cohort expected in first half of 2019

Shares of South San Francisco-based Achaogen, Inc. fell more than 12 percent in Monday trading after the company signaled that it began a review of strategic alternatives that could include a sale of the company.

Allergan indicated that it “has shifted [its] priority from expanding the Waco site to investing significantly in our existing operations.” However, the company spokesperson said that Allergan “remains committed to our eye care business and operations in Waco.”

Cambridge, Mass.-based AVEO Oncology hit the mark in its Phase III study of a treatment for highly refractory advanced or metastatic renal cell carcinoma (RCC). The company said its drug tivozanib met its primary endpoint of demonstrating a statistically significant benefit in progression-free survival (PFS).

Tara Karimi, co-founder and chief executive officer of Cemvita, spoke with BioSpace about the company and the amazing things it’s working on to solve problems for human exploration to deep space by in-situ biomanufacturing of human life supplies.

BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.

Businesses in Pharma & Biotech and in Consumer Health – including capsule and combined ingredient and dosage form offerings – continued to drive growth

Cristal Therapeutic announced today the first patient has been dosed in its Phase 2 clinical trial of lead nanomedicine candidate CPC634 for patients with platinum-resistant ovarian cancer.